BofA raised the firm’s price target on Teva (TEVA) to $42 from $38 and keeps a Buy rating on the shares. The firm adjusted several targets in conjunction with its Q1 preview for its large-cap pharma and small-to-mid cap biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva call volume above normal and directionally bullish
- Teva announces FDA approval of Ponlimsi biosimilar to Prolia
- Teva announces FDA, EMA acceptance of proposed Xolair biosimilar applications
- Teva put volume heavy and directionally bearish
- Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?